

NGS bacterial meningitis test

February 2019—Viracor Eurofins launched a 16S Next Generation Sequencing Bacterial Meningitis test for use in patients suspected of having bacterial meningitis. Physicians will receive test results for difficult-to-diagnose immunocompromised patients within three business days from specimen receipt.

Viracor Eurofins amplifies the 16S gene using PCR, followed by the use of next-generation sequencing, to identify and report the bacterial pathogen in a patient's CSF sample. The assay was validated to include the most common bacterial pathogens associated with meningitis: *Streptococcus pneumoniae*, *Neisseria meningitidis*, *Haemophilus influenzae*, *Listeria monocytogenes*, *Streptococcus agalactiae*, and *Escherichia coli* as well as other less common pathogens that may be clinically important in immunocompromised patient populations.

[Viracor Eurofins](#), 800-305-5198